Unity Biotechnology Inc (UBX) Return on Investment ROI from the first quarter of 2025 to first quarter of 2024 and for the year 2025, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket
 


Unity Biotechnology Inc   (NASDAQ: UBX)


Unity Biotechnology Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Unity Biotechnology Inc's ROI in the first quarter of 2025?
Unity Biotechnology Inc recorded a cumulative net loss of $-28 million during 12 months ending in the first quarter of 2025, resulting in a negative return on investment (ROI) of -82.88%.

Within the Healthcare sector 682 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2024 from 3593 to 4046.

Definition and Formula of Return on Investment



Return On Investment (Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
Y / Y Investment Change TTM -35.54 % -32.79 % -45.07 % -48.93 % -43.49 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 21 28 38 45 51
Return On Investment (TTM) -82.88 % -63.94 % -45.72 % -60.62 % -72.9 %
UBX's Overall Ranking # 4046 # 3593 # 3753 # 3768 # 0
Seq. Investment Change TTM -18.36 % -2.44 % -7.65 % -12.36 % -14.88 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -28 -26 -19 -27 -38




Return On Investment UBX's Ranking
Within: No.
Industry # 315
Sector # 683
Overall # 4046

Return On Investment Statistics
High Average Low
-44.92 %
-58.24 %
-82.88 %
(Dec 31 2018)   (Mar 31 2025)







Financial Statements
Unity Biotechnology Inc's I. Quarter Investments $ 21 Millions UBX's Balance sheet
Unity Biotechnology Inc's I. Quarter Income $ -7 Millions Quarterly UBX's Income Statement
UBX's Income by Division See UBX's Income by Division


UBX Annual Return On Investment (Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
Total Investments in Millions 28 32 105 108 142
Y / Y Investment Growth -12.53 % -68.99 % -3.11 % -23.8 % 5.86 %
Net Income in Millions -26 -40 -60 -61 -94
Y / Y Net Income Growth - - - - -
Annual Return On Investment -91.51 % -122.75 % -57.22 % -56.18 % -66.15 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
UBX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for UBX's Competitors
Subscribers only: Roi for Unity Biotechnology Inc's Suppliers
Subscribers only: Return On Investment for UBX's Customers

Other Ratios
UBX's Roa UBX's Inventory Turnover Ratio UBX's Growth Rates UBX's Dividend Statistics
UBX's Profitability Ratios UBX's Asset Turnover Ratio UBX's Dividend Growth
UBX's Roe UBX's Valuation Ratios UBX's Financial Strength Ratios UBX's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector ROI


Date modified: 2026-09-26T07:34:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.